In the present study, the KL-6 concentrations in COVID-19 patients by two different methods, CLEIA and FEIA by Lumipulse G600II (Fujirebio, Europe, Ghent, Belgium) and AIA360 (Tosoh, Biosciences, Tokyo, Japan) system, were evaluated. The gene discussed is MUC1; the disease is COVID-19.